IFP Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.75K Hold
233
– – ﹤0.01% 3561
2026
Q2
$8.65K Buy
233
+231
+11,550% +$7.01K ﹤0.01% 3486
2026
Q1
$68 Sell
2
-4
-67% -$113 ﹤0.01% 4794
2025
Q4
$163 Hold
6
– – ﹤0.01% 4509
2025
Q3
$241 Buy
+6
New +$226 ﹤0.01% 4358
2025
Q2
– Hold
0
– – – 3928
2025
Q1
– Sell
-3
Closed -$99 – 4302
2024
Q4
$99 Buy
+3
New +$141 ﹤0.01% 4033
2021
Q4
– Sell
-29
Closed -$1K – 3375
2021
Q3
$1K Hold
29
– – ﹤0.01% 2964
2021
Q2
$2K Hold
29
– – ﹤0.01% 2707
2021
Q1
$1K Hold
29
– – ﹤0.01% 2779
2020
Q4
$1K Hold
29
– – ﹤0.01% 2718
2020
Q3
$1K Hold
29
– – ﹤0.01% 2587
2020
Q2
$2K Buy
+29
New +$1.34K ﹤0.01% 2350
2019
Q4
– Sell
-18
Closed -$680 – 2823
2019
Q3
$1K Buy
+18
New +$745 ﹤0.01% 2817
2018
Q3
– Sell
-52
Closed -$4K – 3800
2018
Q2
$4K Buy
+52
New +$4.54K ﹤0.01% 3329
2016
Q3
– Sell
-225
Closed -$9K – 3882
2016
Q2
$9K Buy
+225
New +$11.1K ﹤0.01% 2781
2016
Q1
– Sell
-230
Closed -$15K – 2363
2015
Q4
$15K Buy
+230
New +$15.1K ﹤0.01% 2321

Other funds holding AGIO

IFP Advisors's AGIO Position: Q3 2026 in Review

IFP Advisors held its Agios Pharmaceuticals (AGIO) position steady in Q3 2026 at 233 shares worth $7.75K. The position accounts for ﹤0.01% of the portfolio, ranked #3561.

IFP Advisors first reported a position in AGIO in Q4 2015 and has held it in 16 quarters since. The position peaked at $15K in Q4 2015. 243 funds tracked by Wall St. Rank hold AGIO as of Q3 2026.

  • IFP Advisors held 233 shares of Agios Pharmaceuticals worth $7.75K as of Q3 2026.
  • IFP Advisors left its Agios Pharmaceuticals share count unchanged in Q3 2026.
  • Agios Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #3561 holding.
  • IFP Advisors first reported a position in Agios Pharmaceuticals in Q4 2015 and has held it in 16 quarters since.
  • IFP Advisors's Agios Pharmaceuticals position peaked at $15K in Q4 2015.
  • 243 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.